- Home
- EMBC vs KURA Comparison
EMBC vs KURA Comparison
Compare EMBC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMBC
- KURA
- Stock Information
- Founded
- EMBC 1924
- KURA 2014
- Country
- EMBC United States
- KURA United States
- Employees
- EMBC N/A
- KURA N/A
- Industry
- EMBC Medical/Dental Instruments
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMBC Health Care
- KURA Health Care
- Exchange
- EMBC Nasdaq
- KURA Nasdaq
- Market Cap
- EMBC 753.0M
- KURA 793.2M
- IPO Year
- EMBC N/A
- KURA N/A
- Fundamental
- Price
- EMBC $19.90
- KURA $9.52
- Analyst Decision
- EMBC Buy
- KURA Strong Buy
- Analyst Count
- EMBC 2
- KURA 10
- Target Price
- EMBC $19.00
- KURA $30.13
- AVG Volume (30 Days)
- EMBC 491.4K
- KURA 2.9M
- Earning Date
- EMBC 02-07-2025
- KURA 11-07-2024
- Dividend Yield
- EMBC 3.02%
- KURA N/A
- EPS Growth
- EMBC 9.84
- KURA N/A
- EPS
- EMBC 1.34
- KURA N/A
- Revenue
- EMBC $1,123,100,000.00
- KURA N/A
- Revenue This Year
- EMBC $1.77
- KURA N/A
- Revenue Next Year
- EMBC $1.14
- KURA $106.66
- P/E Ratio
- EMBC $14.81
- KURA N/A
- Revenue Growth
- EMBC 0.21
- KURA N/A
- 52 Week Low
- EMBC $9.93
- KURA $9.40
- 52 Week High
- EMBC $21.48
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- EMBC 60.29
- KURA 24.01
- Support Level
- EMBC $19.16
- KURA $9.40
- Resistance Level
- EMBC $20.22
- KURA $10.02
- Average True Range (ATR)
- EMBC 0.91
- KURA 0.46
- MACD
- EMBC -0.12
- KURA 0.10
- Stochastic Oscillator
- EMBC 22.27
- KURA 8.09
About EMBC Embecta Corp.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.